<?xml version="1.0" encoding="UTF-8"?>
<p>The successful demonstration of strong systemic and mucosal immunogenicity in preclinical studies has led to several clinical trials to exam the safety and immunogenicity of NoV VLP-based vaccines in humans (Table 
 <xref rid="Tab00083" ref-type="table">8.3</xref>) 
</p>
